AstraZeneca plc (ADR) (AZN) announced on Tuesday that it has once again rejected Pfizer, Inc. (NYSE:PFE) offer to take over the company. The announcement came just a day after the American pharmaceutical giant attempted to lure the British drug maker with a $106 billion offer. Pfizer Inc. (NYSE:PFE) shares after opening at $29.14 moved to $29.48 on last trade day and at the end of the day closed at $29.02. Company price to sales ratio in past twelve months was calculated as 3.59 and price to cash ratio as 5.71. Pfizer Inc. (NYSE:PFE) showed a negative weekly performance of -6.39%.
The pharmaceutical giant Merck & Co. Inc. (NYSE:MRK) is pushing forward its pipeline of drugs including a melanoma treatment that is getting priority review by federal regulators but it is also open to making deals that will accelerate its growth, top executives told a gathering of investors in Boston. That was made clear Tuesday, when Merck agreed to sell its consumer care business to the German drug maker Bayer AG for about $14.2 billion, while striking a collaboration with Bayer to co-develop and market cardiovascular disease treatments. Merck & Co., Inc. (NYSE:MRK) shares fell -2.22% in last trading session and ended the day on $55.84. MRK return on equity ratio is recorded as 12.40% and its return on assets is 5.70%. Merck & Co., Inc. (NYSE:MRK) yearly performance is 27.72%.
Boston Scientific Corporation, (NYSE:BSX) a global medical technology leader, has joined Optum Labs as the Founding Medical Device Partner to help pioneer new research into effective treatments for heart failure and related cardiac conditions. Optum Labs is an open collaborative healthcare research and innovation centre founded in 2013 by Optum, Mayo Clinic and also joined by AARP as founding consumer advocate organisation. Boston Scientific Corporation (NYSE:BSX) shares moved down -1.39% in last trading session and was closed at $12.77, while trading in range of $12.63 – $13.01. Boston Scientific Corporation (NYSE:BSX) year to date (YTD) performance is 6.24%.
Bristol-Myers Squibb Company (NYSE:BMY) announced that Brian Daniels, senior vice president, Global Development and Medical Affairs, will be retiring from the company, effective July 1, 2014. Bristol-Myers Squibb Co (NYSE:BMY) weekly performance is 1.36%. On last trading day company shares ended up $50.77. Bristol-Myers Squibb Co (NYSE:BMY) distance from 50-day simple moving average (SMA50) is -1.99%. Analysts mean target price for the company is $54.94.
Leave a Reply